
Pixclara
(floretyrosine F 18)



THE PLAN IS IN THE SCAN

Advance Your Expertise in Pixclara® (^{18}F-FET) PET Imaging Interpretation

Explore educational modules focused on image interpretation, case-based review, and clinical perspectives in neuro-oncology imaging.

Featured Modules

MODULE 1:

The Referring Physician's Perspective — The Foundation of ^{18}F-FET PET Reader Training

Gain foundational insight into the clinical utility of ^{18}F-FET PET imaging, patient selection, referral considerations, and its role in neuro-oncology care.



Nancy Ann Oberheim Bush, MD, PhD
Wendy Olson Wood-Smith Endowed Professor
Clinical Director, Division of Neuro-Oncology
Department of Neurological Surgery and Neurology
University of California San Francisco

MODULE 2:

The Interpreting Physician Perspective — ^{18}F-FET PET Reader Training

Explore interpretation methodologies, imaging protocols, qualitative and quantitative assessments, and best practices for accurate scan interpretation.



Jonathan McConathy, MD, PhD
Director, Division of Molecular Imaging and Therapeutics (MI&T)
UAB Heersink School of Medicine

MODULE 3:

A Comprehensive Case Study Review — ^{18}F-FET PET Reader Training

Review advanced case studies and learn practical approaches for challenging imaging scenarios and how accurate imaging impacts patient management decisions.



Michael Veronesi, MD, PhD
Associate Professor of Radiology
University of Wisconsin

MODULE 4:

Interpretation Skill Development — ^{18}F-FET PET Reader Training

Apply your learnings through hands on case-based learning designed to strengthen your interpretation proficiency and clinical confidence.

To Access Training Modules Visit TelixU

INDICATIONS AND USAGE
PIXCLARA is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

RISK FOR MISINTERPRETATION
Image misinterpretation may occur with PIXCLARA PET. A negative image does not rule out the presence of recurrent or progressive glioma and a positive image does not confirm the presence of recurrent or progressive glioma. Equivocal findings may occur with PIXCLARA PET, including low-level or atypical uptake patterns, which may result in false positive or false negative interpretations.

Interpret PIXCLARA PET findings with caution and correlate results with available clinical evaluations, such as histopathology, cross-sectional imaging, and/or clinical history to support appropriate clinical decision-making.

RADIATION RISKS
PIXCLARA contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PIXCLARA was evaluated in 382 patients with gliomas. Among these 382 patients, 371 adult patients received at least one intravenous dose of PIXCLARA at a mean activity of 204 ± 18 MBq (5.5 ± 0.47 mCi). The remaining 11 pediatric patients received at least one intravenous dose of PIXCLARA at a mean activity of 155 ± 53.5 MBq (4.2 ± 1.4 mCi).

The mean age of the patients was 57 years (range: 5 years to 86 years). Sex was 59% male, 37% female, and 3% unreported. Distribution by race was 26% White, 6% Asian, <1% Black or African American, and 67% other or unreported. Distribution by ethnicity was 3% Hispanic/Latino, 96% non-Hispanic/Latino, and <1% unknown or unreported.

Adverse reactions that occurred in ≥0.5% of patients receiving PIXCLARA were headache (0.5%).

Adverse reactions that occurred in <0.5% of patients were nausea, injection site reaction, fatigue, and malaise.

Adverse Reactions in Pediatric Patients
Overall, the safety profile observed in pediatric patients from the clinical study was consistent with the safety profile in adult patients.

Please note that this information is not comprehensive.
Please see the Full Prescribing Information at pixclara.com/prescribinginformation
You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
You may also report adverse reactions to Telix Pharmaceuticals (US) by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com.

Telix

The Telix Pharmaceuticals and Pixclara® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates.
© 2026 Telix Pharmaceuticals Ltd. All rights reserved. XXXXXXX 9/2026